Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (341-350 of 501) with videos related to

Pageof 51
Sort By:
British Journal of Cancer|April 9, 2026
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarkerElena Sophia Lindner, Jakob Admard, German Demidov, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
The Journal of Investigative Dermatology|May 14, 2004
Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasisLéon C L T van Kempen, Friedegund Meier, Mikala Egeblad, et al.
Plos One|March 12, 2015
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanomaLisa Zimmer, Julia Vaubel, Peter Mohr, et al.
Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.
Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2011
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanomaThomas K Eigentler, Benjamin Weide, Filippo de Braud, et al.
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.
Experimental Dermatology|June 16, 2016
GSTP1 does not modify MC1R effects on melanoma riskGemma M Daley, David L Duffy, Annette Pflugfelder, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019Paolo A Ascierto, Carlo Bifulco, Jerome Galon, et al.
Pageof 51

Showing results (341-350 of 501) with videos related to

Sort By:
Pageof 51
British Journal of Cancer|April 9, 2026
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarkerElena Sophia Lindner, Jakob Admard, German Demidov, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
The Journal of Investigative Dermatology|May 14, 2004
Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasisLéon C L T van Kempen, Friedegund Meier, Mikala Egeblad, et al.
Plos One|March 12, 2015
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanomaLisa Zimmer, Julia Vaubel, Peter Mohr, et al.
Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.
Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2011
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanomaThomas K Eigentler, Benjamin Weide, Filippo de Braud, et al.
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.
Experimental Dermatology|June 16, 2016
GSTP1 does not modify MC1R effects on melanoma riskGemma M Daley, David L Duffy, Annette Pflugfelder, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019Paolo A Ascierto, Carlo Bifulco, Jerome Galon, et al.
Pageof 51